Therefore, factors other than PD-L1 expression, including tumor-infiltrating lymphocytes and tumor-associated MDSCs, may be influenced by aging, and thus, may drive variable responses to PD-1/PD-L1 inhibitors. Here, CD274 is linked to neoplasm.